carbostyril has been researched along with Disease Exacerbation in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.11) | 18.2507 |
| 2000's | 17 (17.89) | 29.6817 |
| 2010's | 64 (67.37) | 24.3611 |
| 2020's | 12 (12.63) | 2.80 |
| Authors | Studies |
|---|---|
| Ahluwalia, N; Campbell, D; Chilvers, M; Davies, JC; Harris, RS; McNamara, J; Naehrlich, L; Paz-Diaz, H; Saunders, C; Sawicki, GS; Sermet-Gaudelus, I; Shih, JL; Wainwright, CE | 1 |
| Guimbellot, JS; Heltshe, SL; Jain, M; Jovanovic, B; Rowe, SM; Sagel, SD; Secunda, KE | 1 |
| Alcazar, B; Barrecheguren, M; Kostikas, K; Mezzi, K; Miravitlles, M; Shen, S; Soler-Cataluña, JJ; Wedzicha, JA | 1 |
| Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Olsson, P; Patalano, F; Pfister, P; Roche, N; Wedzicha, JA | 1 |
| Françoise, A; Héry-Arnaud, G | 1 |
| Callejas-Valera, JL; Gillenwater, AM; Richards-Kortum, RR; Schwarz, RA; Tan, MT; Vigneswaran, N; Wu, JG | 1 |
| Abely, M; Biouhee, T; Bui, S; Burgel, PR; Chiron, R; Corvol, H; Dehillotte, C; Durieu, I; Hubert, D; Lemonnier, L; Macey, J; Marguet, C; Martin, C; Mely, L; Munck, A; Murris-Espin, M; Paillasseur, JL; Porzio, M; Prevotat, A; Reix, P; Sermet-Gaudelus, I; Silva, JD | 1 |
| Barkhof, F; Cree, BAC; Giovannoni, G; Hartung, HP; Knappertz, V; Krieger, S; Li, T; Lublin, F; Montalban, X; Pia Sormani, M; Steinerman, JR; Tansy, AP; Uccelli, A; Uitdehaag, BMJ | 1 |
| Dias, S; Fortescue, R; Janjua, S; Mathioudakis, AG; Sharif, S; Threapleton, CJ; Walker, RA | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Adams, SG; Peters, JI | 1 |
| Konstan, MW; Millar, SJ; Morgan, WJ; Pasta, DJ; VanDevanter, DR; Wagener, JS | 1 |
| Davies, JC; Elizabeth Tullis, D; Flume, PA; Higgins, M; Niknian, M; Rodriguez, S; Wagener, JS; Wainwright, CE | 1 |
| Mayer-Hamblett, N; VanDevanter, DR | 1 |
| Aalamian-Mattheis, M; Castellani, W; Clemens, A; Gaga, M; Greulich, T; Kostikas, K; Lane, S; Marin, JM; Ninane, V; Nunez, X; Patalano, F; Vogelmeier, CF | 1 |
| Casciaro, R; Costa, S; Dang, P; Majo, F; Ros, M | 1 |
| Buhl, R; Criée, CP; Kardos, P; Lossi, NS; Vogelmeier, CF; Worth, H | 1 |
| Caulin, C; El-Naggar, AK; Heymach, JV; Myers, JN; Wang, B; Wang, J; William, WN; Xie, T | 1 |
| Han, F; Kong, J; Lai, M; Liu, Y; Shen, E; Sun, W; Wan, L; Wu, Y; Xie, S; Xu, E; Yu, T; Yu, W; Zhang, H; Zhang, L; Zhou, Y | 1 |
| Amer, AO; Badr, A; Caution, K; Cormet-Boyaka, E; Dakhlallah, D; Hall-Stoodley, L; Hamilton, K; Hayes, D; Kirkby, SE; Klamer, BG; Kopp, BT; Krause, K; McCoy, KS; Parinandi, NL; Partida-Sanchez, S; Robledo-Avila, F; Shrestha, C; Tazi, MF; Tumin, D; Zhang, X | 1 |
| Alexander, DK; Cho, DY; Grayson, JW; Hill, HS; Lim, DJ; Mackey, C; Peña Garcia, JA; Skinner, D; Weeks, CG; Woodworth, BA; Zhang, S | 1 |
| Bengtsson, L; Bessonova, L; Bilton, D; Elbert, A; Higgins, M; Konstan, MW; Marshall, BC; Nyangoma, S; Sawicki, GS; Sewall, A; Simard, C; Tian, S; Volkova, N | 1 |
| Connett, GJ; Hammond, JA | 1 |
| Anzueto, AR; Banerji, D; Fogel, R; Kostikas, K; Larbig, M; Mezzi, K; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Gutzwiller, FS; Kostikas, K; Larbig, M; Mackay, A; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Boyle, MP; Jiang, JG; Konstan, MW; Marigowda, G; McColley, SA; Ramsey, BW; Rubin, JL; Stuart Elborn, J; Vera-Llonch, M; Wainwright, CE; Waltz, D | 1 |
| Bahat-Dinur, A; El-Seid, S; Kaplan, D; Kraus, M; Peled, C; Tzvi-Ran, LR | 1 |
| Bonk, MP; Hadjiliadis, D; Rey, MM | 1 |
| Flume, PA; Kosinski, M; Marigowda, G; Quittner, AL; Suthoff, ED | 1 |
| Fogel, R; Fucile, S; Goyal, P; Jenkins, C; Kostikas, K; Mezzi, K; Shen, S; Singh, D; Tsiligianni, I; Wedzicha, JA | 1 |
| De Wachter, E; Vanderhelst, E; Verbanck, S; Vincken, S | 1 |
| Beekman, JM; Engelhardt, JF; Evans, TIA; Fiorino, DF; Gibson-Corley, KN; Gray, JS; Jiang, L; Liang, B; Moll, SR; Negulescu, P; Park, SY; Rosen, BH; Rotti, PG; Sun, X; Tran, DM; Van Goor, F; Vonk, AM; Winter, MC; Woody, L; Yan, Z; Yang, Y; Yi, Y; Zhang, Y; Zhou, W | 1 |
| Bratcher, PE; Chioccioli, M; Cicuta, P; Feriani, L; Kotar, J | 1 |
| Balfour-Lynn, IM | 1 |
| Chae, JY; Kim, JW; Moon, du G; Oh, MM; Park, MG; Yoon, CY | 1 |
| Falkai, P; Schmitt, A | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Calero, C; Lopez-Campos, JL; Quintana-Gallego, E | 1 |
| Choi, YJ; Jo, J; Kang, YK; Lee, JJ; Park, I; Park, JH; Ryoo, BY; Ryu, JS; Ryu, MH; Tan, E; Yoo, C | 1 |
| Arrasate, C; Banerji, D; Chen, H; D'Andrea, P; Decramer, M; Ficker, JH; Niewoehner, DE; Sandström, T; Taylor, AF; Wedzicha, JA | 1 |
| Balis, FM; Belasco, J; Dombi, E; Fox, E; Gillespie, A; Goldman, S; Kieran, MW; Kim, A; Korf, BR; Martin, S; Patronas, N; Perentesis, JP; Reddy, A; Salzer, W; Solomon, J; Steinberg, SM; Widemann, BC; Wolters, PL; Wright, JJ | 1 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Barnett, MH; Boggild, M; Brew, BJ; Broadley, SA; Butzkueven, H; Carroll, WM; Heard, R; Hodgkinson, S; Kermode, AG; Kilpatrick, TJ; King, J; Lechner-Scott, J; Macdonell, RA; Marriott, M; Mason, DF; McCombe, PA; Parratt, J; Pollard, JD; Reddel, SW; Shaw, CP; Slee, M; Spies, J; Taylor, BV; Willoughby, E | 1 |
| Chen, MF; Chen, WC; Chung, YH; Kuan, FC; Lee, KD; Lin, PY; Lu, MS; Yen, TC | 1 |
| Armstrong, AJ; Carducci, MA; Damber, JE; Edenbrandt, L; Forsberg, G; Hansen, M; Kaboteh, R; Morris, MJ; Nordle, Ö; Pili, R; Stadler, WM | 1 |
| Billia, M; Chin, J; Mazzola, CR; Siddiqui, KM | 1 |
| Ulrik, CS | 1 |
| Borowitz, D; Davies, JC; Drevinek, P; Gilmartin, G; Griese, M; Jiang, Y; Konstan, MW; McKone, EF; Munck, A; Plant, B; Ratjen, F; Sermet-Gaudelus, I; Wainwright, C | 1 |
| Altman, P; Bucchioni, E; Cameron, R; del Olmo, R; Lu, C; Papi, A; Quinn, M; Rossi, A; van der Molen, T; Wehbe, L; Young, D | 1 |
| Abbasi, MM; Hamishehkar, H; Jahanban-Esfahlan, R; Khiavi, MM; Monfaredan, A; Seidi, K | 1 |
| Beasley, RW; Clay, M; Donohue, JF; Hederer, BM; Kim, HJ; Mehta, R; Moton, A; Nelson, HS | 1 |
| Ahrens, R; Elborn, JS; Johnson, C; Konstan, MW; Munck, A; Plant, BJ; Rodriguez, S | 1 |
| Chen, MF; Chen, PT; Chen, WC; Hsieh, CC; Lin, PY; Wu, CT; Yen, TC | 1 |
| Bothwell, KD; Hershberger, PA; Johnson, CS; Kuriakose, MA; Merzianu, M; Seshadri, M; Shaurova, T; Suresh, A | 1 |
| Chen, X; Han, X; Jiang, K; Li, S; Wang, B; Zhou, L | 1 |
| Constantinescu, CS; Constantinescu, SE | 1 |
| Mayer, M | 1 |
| Hainke, U; Thomas, K; Ziemssen, T | 1 |
| Einecke, D | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Clark, MR; Liarski, VM; Trotter, K | 1 |
| Au, DH; Carson, SS; Feemster, LC; Krishnan, JA; Lindenauer, PK; Shieh, MS; Stefan, MS | 1 |
| Armstrong, AJ; George, D; Halabi, S; Harrison, MR; Healy, P; Humeniuk, MS; Kephart, J; Martinez, E; Mundy, K; Szmulewitz, R; Winters, C | 1 |
| Goss, CH; Huang, X; Konstan, MW; Lubarsky, B; Marigowda, G; Mayer-Hamblett, N; McKone, EF; Millar, SJ; Morgan, W; Moss, RB; Pasta, DJ; Rubin, J; Sawicki, GS; Tian, S; Waltz, D | 1 |
| Annus, A; Majlath, Z; Vecsei, L | 1 |
| André, F; Barrios, CH; Blackwell, K; Bonnefoi, H; Campone, M; Cortes, J; Denduluri, N; Deudon, S; Kahan, Z; Musolino, A; Neven, P; Shi, MM; Soliman, H; Squires, M; Zhang, Y | 1 |
| Addison, CL; Bane, A; Filion, ML; Goffin, J; Gupta, A; Hao, D; Khomani, A; Laurie, SA; Leighl, NB; Levine, MN; Pond, GR; Seely, J | 1 |
| Sikich, L | 1 |
| Avallone, H; Cao, K; Capell, BC; Chen, X; Collins, FS; Conneely, KN; Erdos, MR; Faddah, DA; Ganesh, SK; Kolodgie, FD; Nabel, EG; Olive, M; Qu, X; San, H; Tavarez, UL; Virmani, R | 1 |
| Bellamy, R; Payne, B | 1 |
| Schwankhaus, J; Singh, S | 1 |
| Feldman, EJ | 2 |
| Emery, C; Fukuchi, Y; Higgins, M; Hosoe, M; Kato, M; Kramer, B; Makita, H; Uemura, K | 1 |
| Azuma, T; Fujiwara, S; Itoh, T; Kawakami, F; Kutsumi, H; Morita, Y; Toyonaga, T; Yoshida, M | 1 |
| Rexer, H | 1 |
| Boyko, A; Comi, G; Filippi, M; Jeffery, D; Kappos, L; Montalban, X; Rocca, MA | 1 |
| Graham-Rowe, D | 1 |
| Lindenauer, PK; Pekow, PS; Rothberg, MB; Shieh, MS; Stefan, MS | 1 |
| Chong, J; Karner, C; Poole, P | 1 |
| Dowers, KL; Lappin, MR; Olver, C; Radecki, SV | 1 |
| Abbruzzese, JL; Alpaugh, RK; Beard, M; Cohen, SJ; Ho, L; Hudes, GR; Lewis, NL; McLaughlin, S; Meropol, NJ; Perez-Ruixo, JJ; Ranganathan, S; Rogatko, A; Thistle, AM; Verhaeghe, T; Wang, H; Weiner, LM; Wright, JJ | 1 |
| Adjei, AA; Bruzek, L; Erlichman, C; Geyer, S; Hanson, LJ; Hillman, S; Kaufmann, SH; Marks, RS; Mauer, A; Vokes, EE; Wright, JJ | 1 |
| Abrams, RA; Regine, WF; Rich, TA; Safran, H; Willett, CG | 1 |
| Dowsett, M; Ellis, P; Hickish, T; Houston, S; Howes, A; Johnston, SR; Kelland, L; Michiels, B; Palmer, P; Perez-Ruixo, JJ; Salter, J | 1 |
| Khuri, FR | 1 |
| Adjei, AA; Ahmann, G; Alsina, M; Belle, AN; Bruzek, LM; Cantor, AB; Dalton, WS; Djulbegovic, B; Fonseca, R; Gerbino, E; Greipp, PR; Kaufmann, SH; Overton, RM; Price-Troska, T; Sebti, SM; Sullivan, D; Wilson, EF; Wright, JJ | 1 |
| Ahuja, N; Lloyd, AJ | 1 |
| Cohen, K; Fouladi, M; Helton, KJ; Holmes, E; Laningham, F; Nicholson, HS; Pollack, IF; Speights, RA; Wright, J; Zhou, T | 1 |
| Kozai, S; Ohashi, Y; Sakaki, H; Suzuki, T; Tajika, T; Wada, T | 1 |
| Klinberg, NM; Mar'iandyshev, AO; Moroz, MI; Shonbina, AI | 1 |
| Boyce, S; Carlson, E; Hill, RG; Martin, JE; Rupniak, NM; Webb, JK | 1 |
21 review(s) available for carbostyril and Disease Exacerbation
| Article | Year |
|---|---|
The Microbiome in Cystic Fibrosis Pulmonary Disease.
Topics: Aminophenols; Animals; Archaea; Bacteria; Biomarkers; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Disease Progression; Dysbiosis; Fungi; Gastrointestinal Microbiome; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung; Mammals; Metagenomics; Microbiota; Organ Specificity; Prognosis; Quinolones; Viruses | 2020 |
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Load; Bayes Theorem; Bias; Disease Progression; Female; Forced Expiratory Volume; Humans; Macrolides; Male; Middle Aged; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Tetracyclines; Treatment Outcome | 2021 |
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
Topics: Aminophenols; Aminopyridines; Anti-Bacterial Agents; Benzodioxoles; Chloride Channel Agonists; Clinical Trials as Topic; Comparative Effectiveness Research; Cystic Fibrosis; Disease Progression; Drug Combinations; Humans; Pseudomonas Infections; Quinolones; Standard of Care; Treatment Outcome | 2017 |
Clinical papers of the year 2018 - Cystic fibrosis.
Topics: Administration, Inhalation; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Azithromycin; Benzodioxoles; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Chloride Channel Agonists; Cough; Cross Infection; Cystic Fibrosis; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Indoles; Lung Transplantation; Microbiological Techniques; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Nebulizers and Vaporizers; Proton Pump Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Randomized Controlled Trials as Topic; Saline Solution, Hypertonic; Specimen Handling; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 2020 |
Symptom variability in COPD: a narrative review.
Topics: Activities of Daily Living; Bronchodilator Agents; Clinical Trials as Topic; Disease Progression; Ethanolamines; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Patient Care Management; Periodicity; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Surveys and Questionnaires; Symptom Assessment | 2013 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neur
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antioxidants; Australia; Clinical Trials, Phase III as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Disease Management; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; New Zealand; Nitriles; Quinolones; Randomized Controlled Trials as Topic; Therapies, Investigational; Toluidines; Transplantation, Autologous; Treatment Outcome | 2014 |
Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Transitional Cell; Disease Progression; Humans; Molecular Targeted Therapy; Quinolones; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2014 |
[The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Disease Progression; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2014 |
Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Topics: Administration, Oral; Animals; Brain; Disease Models, Animal; Disease Progression; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2016 |
Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neuritis, Autoimmune, Experimental; Quinolones | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Overview of pathophysiology and treatment of human lupus nephritis.
Topics: Abatacept; Antibodies, Monoclonal, Humanized; Autoantibodies; Biopsy; Cyclophosphamide; Dendritic Cells; Disease Progression; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammation; Interferon Type I; Kidney Failure, Chronic; Lupus Nephritis; Maintenance Chemotherapy; Mycophenolic Acid; Prognosis; Quinolones; Recombinant Fusion Proteins; Remission Induction; Ribonucleosides; Severity of Illness Index; T-Lymphocytes, Helper-Inducer; Treatment Outcome; Vimentin | 2016 |
Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod.
Topics: Animals; Brain; Disease Progression; Drug Development; Humans; Kynurenine; Molecular Targeted Therapy; Multiple Sclerosis; Neuroprotective Agents; Quinolones; Young Adult | 2018 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Tuberculosis in people with HIV.
Topics: Disease Progression; HIV Infections; Humans; Meta-Analysis as Topic; Quinolones; Survival Analysis; Time Factors; Tuberculosis; United States Food and Drug Administration | 2007 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome | 2006 |
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchodilator Agents; Cost-Benefit Analysis; Disease Progression; Ethanolamines; Formoterol Fumarate; Hospitalization; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gemcitabine; Humans; Paclitaxel; Quinolones; Radiotherapy, Conformal; Treatment Outcome | 2003 |
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones | 2003 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Acute Disease; Aged; Alkyl and Aryl Transferases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Remission Induction; Signal Transduction; Treatment Outcome | 2005 |
32 trial(s) available for carbostyril and Disease Exacerbation
| Article | Year |
|---|---|
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.
Topics: Aminophenols; Benzodioxoles; Child; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Homozygote; Humans; Indoles; Mutation; Quinolones | 2022 |
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires | 2020 |
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
Topics: Adult; Atrophy; Brain; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Quinolones; Spinal Cord; Treatment Outcome | 2020 |
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Disease Progression; Drug Combinations; Drug Substitution; Dyspnea; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Topics: Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Surveys and Questionnaires | 2019 |
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV
Topics: Adolescent; Adult; Aged; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Disease Progression; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; Quinolones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Cystic Fibrosis; Disease Progression; Drug Combinations; Female; Humans; Male; Quality of Life; Quinolones; Recovery of Function; Time Factors; Treatment Outcome | 2019 |
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sex Characteristics; Treatment Outcome | 2019 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Benzimidazoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Sunitinib | 2013 |
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Respiratory System; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cross-Over Studies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Neurofibroma, Plexiform; Neurofibromatosis 1; Quinolones; Treatment Outcome; Young Adult | 2014 |
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Topics: Bone and Bones; Bone Neoplasms; Diagnostic Imaging; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Radiography; Retrospective Studies | 2014 |
Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
Topics: Adolescent; Adult; Aminophenols; Child; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Female; Forced Expiratory Volume; Humans; Male; Mutation; Quinolones; Respiratory Tract Infections; Time Factors; Weight Gain; Young Adult | 2014 |
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Drug Substitution; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome; Vital Capacity | 2014 |
Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Maleates; Middle Aged; Mometasone Furoate; Pregnadienediols; Quinolones; Young Adult | 2015 |
Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.
Topics: Adolescent; Adult; Aminophenols; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Female; Forced Expiratory Volume; Humans; Male; Mutation; Numbers Needed To Treat; Quinolones; Respiratory Function Tests; Surveys and Questionnaires; Sweat; Weight Gain; Young Adult | 2015 |
Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study.
Topics: Alanine; CDX2 Transcription Factor; Disease Progression; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Homeodomain Proteins; Humans; Male; Metaplasia; Middle Aged; Peptides; Precancerous Conditions; Quinolones; Stomach Neoplasms; Trefoil Factor-3 | 2015 |
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quinolones; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Topics: Adolescent; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Forced Expiratory Volume; Homozygote; Humans; Lung; Male; Mutation; Quinolones; Time; Treatment Outcome; Young Adult | 2017 |
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Survival Analysis; Treatment Outcome | 2017 |
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
Topics: Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Diffusion Magnetic Resonance Imaging; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Ontario; Pleural Neoplasms; Protein Kinase Inhibitors; Quinolones; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2017 |
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Clinical Protocols; Disease Progression; Double-Blind Method; Female; Humans; Indans; Japan; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests | 2010 |
A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Disease Progression; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Gastritis, Atrophic; Gastroscopy; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Quinolones; Rabeprazole; Severity of Illness Index; Stomach Neoplasms; Stomach Ulcer | 2011 |
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Disease Progression; Female; Germany; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor A | 2011 |
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Topics: Adult; Brain; Cough; Disease Progression; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Pain; Quinolones | 2012 |
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Carrier Proteins; Disease Progression; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinolones; Treatment Outcome | 2003 |
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Anemia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Farnesyltranstransferase; Female; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Neutropenia; Quinolones; Survival | 2003 |
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinolones; Thrombocytopenia; Treatment Outcome | 2003 |
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Carrier Proteins; Cell Survival; Disease Progression; DNA-Binding Proteins; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Phosphorylation; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; ras Proteins; Salvage Therapy; Signal Transduction; STAT3 Transcription Factor; Trans-Activators | 2004 |
A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Male; Medulloblastoma; Neuroectodermal Tumors; Quinolones; Treatment Outcome | 2007 |
42 other study(ies) available for carbostyril and Disease Exacerbation
| Article | Year |
|---|---|
Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.
Topics: Adolescent; Adult; Age Factors; Aminophenols; Body Mass Index; Body Weight; Child; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Male; Quinolones; Sex Factors; Sweat; Young Adult | 2020 |
COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population.
Topics: Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2020 |
A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis.
Topics: 4-Nitroquinoline-1-oxide; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Disease Progression; Lymphocytes; Mice, Inbred CBA; Mice, Transgenic; Mutation; Oncogene Proteins, Viral; Quinolones; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tongue Neoplasms | 2020 |
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Disease Progression; Drug Combinations; Female; France; Humans; Male; Quinolones; Respiratory Function Tests | 2021 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
In COPD, prophylactic macrolides, but not tetracyclines or quinolones, reduce exacerbations, with fewer serious adverse events.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Disease Progression; Humans; Macrolides; Pulmonary Disease, Chronic Obstructive; Quinolones; Tetracyclines | 2021 |
Relationship of Antibiotic Treatment to Recovery after Acute FEV
Topics: Adolescent; Ambulatory Care; Anti-Bacterial Agents; Child; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Logistic Models; Lung; Male; North America; Prospective Studies; Pseudomonas Infections; Quinolones | 2017 |
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
Topics: Adolescent; Adult; Aminophenols; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Female; Humans; Male; Mucociliary Clearance; Mutation; Outcome Assessment, Health Care; Quinolones; Recovery of Function; Respiratory Function Tests | 2018 |
Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Drug Therapy, Combination; Forced Expiratory Volume; Homozygote; Humans; Italy; Mutation; Quinolones; Surveys and Questionnaires; Treatment Outcome | 2018 |
GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Critical Pathways; Disease Management; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Germany; Glycopyrrolate; Humans; Indans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Practice Guidelines as Topic; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2017 |
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antibodies, Monoclonal; Apoptosis; Carcinogens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Progression; Female; Granzymes; Immunoglobulin G; Immunohistochemistry; Interferon-gamma; Ligands; Mice; Mice, Inbred C57BL; Mouth Neoplasms; Precancerous Conditions; Programmed Cell Death 1 Receptor; Quinolones; STAT1 Transcription Factor | 2017 |
SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Indans; Mice; Phosphoproteins; Protein Isoforms; Quinolones; Sequence Analysis, RNA; Serine-Arginine Splicing Factors; Tumor Cells, Cultured; Up-Regulation | 2019 |
The expression of Mirc1/Mir17-92 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients.
Topics: Adolescent; Adult; Aminophenols; Aminopyridines; Benzodioxoles; Biomarkers; Chloride Channel Agonists; Correlation of Data; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Drug Monitoring; Female; Gene Expression Profiling; Humans; Male; MicroRNAs; Nerve Tissue Proteins; Quinolones; Respiratory Function Tests; Respiratory System; RNA, Long Noncoding; Sputum | 2018 |
l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.
Topics: Aminophenols; Anti-Bacterial Agents; Biofilms; Chronic Disease; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Methionine; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Rhinitis; Sinusitis | 2018 |
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.
Topics: Adolescent; Adult; Aminophenols; Child; Child, Preschool; Chloride Channel Agonists; Cystic Fibrosis; Disease Progression; Female; Humans; Infant; Male; Quinolones; Registries; Respiratory Function Tests; Treatment Outcome; United Kingdom; United States | 2018 |
The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Female; Homozygote; Humans; Lung; Membrane Transport Modulators; Mutation; Patient Care Management; Quinolones; Respiratory Function Tests; Symptom Flare Up; Treatment Outcome | 2018 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
Necrotizing Otitis Externa-Analysis of 83 Cases: Clinical Findings and Course of Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Disease Progression; Female; Hospitalization; Humans; Male; Middle Aged; Otitis Externa; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome | 2019 |
Cystic Fibrosis: Emerging Understanding and Therapies.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Child; Chronic Disease; Combined Modality Therapy; Comprehension; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Management; Disease Progression; Drug Approval; Female; Genetic Predisposition to Disease; Humans; Lung Transplantation; Male; Prognosis; Quinolones; Risk Assessment; Severity of Illness Index; Survival Analysis; United States; United States Food and Drug Administration | 2019 |
Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
Topics: Adult; Aminophenols; Aminopyridines; Benzodioxoles; Breath Tests; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Combinations; Exhalation; Female; Humans; Male; Nitric Oxide; Prospective Studies; Quinolones; Young Adult | 2019 |
In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis.
Topics: Aminophenols; Animals; Animals, Genetically Modified; Animals, Newborn; Blood Glucose; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Disease Progression; Female; Ferrets; Gene Knock-In Techniques; Genitalia, Male; Gestational Age; Humans; Male; Mutation; Pancreas, Exocrine; Pregnancy; Quinolones; Respiratory Tract Infections; Translational Research, Biomedical | 2019 |
Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells.
Topics: Algorithms; Aminophenols; Aminopyridines; Benzodioxoles; Bronchi; Cilia; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Epithelial Cells; Genotype; Humans; Microscopy; Oscillometry; Phenotype; Quinolones; Video Recording | 2019 |
Positive culture for extended-spectrum β-lactamase during acute prostatitis after prostate biopsy is a risk factor for progression to chronic prostatitis.
Topics: Aged; Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Blood; Cefoxitin; Disease Progression; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Image-Guided Biopsy; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Prostate; Prostatitis; Quinolones; Urine | 2013 |
Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Biomarkers; Disease Progression; Histone Deacetylase Inhibitors; Humans; Piperazines; Quinolones; Schizophrenia | 2013 |
Drug may slow progression and increase prostate cancer survival. A Duke study is one of three recently published investigations that reflect progress against the disease that affects millions of men.
Topics: Antineoplastic Agents; Disease Progression; Humans; Male; Prostatic Neoplasms; Quinolines; Quinolones; Survival Analysis | 2014 |
IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.
Topics: 4-Nitroquinoline-1-oxide; Animals; Arginase; Carcinoma, Squamous Cell; Case-Control Studies; CD11b Antigen; Cells, Cultured; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; HLA-DR Antigens; Humans; Interleukin-6; Lipopolysaccharide Receptors; Male; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells; Neoplasm Staging; Phosphorylation; Quinolones; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Time Factors; Treatment Outcome; Tumor Burden | 2014 |
Oral and IV dosages of doxorubicin-methotrexate loaded- nanoparticles inhibit progression of oral cancer by down- regulation of matrix Methaloproteinase 2 expression in vivo.
Topics: 4-Nitroquinoline-1-oxide; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Male; Matrix Metalloproteinase 2; Methotrexate; Mouth Neoplasms; Nanoparticles; Quinolones; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling.
Topics: 4-Nitroquinoline-1-oxide; Animals; Calcitriol; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Progression; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Interleukin-6; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Microscopy, Fluorescence; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor; Tumor Burden; Vitamins; Xenograft Model Antitumor Assays | 2015 |
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Carcinogens; Carcinoma, Squamous Cell; Disease Progression; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Neoplasms; Neoplasm Transplantation; Quinolones | 2015 |
Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Cystic Fibrosis; Data Interpretation, Statistical; Disease Progression; Drug Approval; Drug Combinations; Drug Costs; Evidence-Based Medicine; Humans; Lung; Quinolones; Surveys and Questionnaires; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
[Narrowing indications for inhaled steroids in COPD].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Disease Progression; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Use of Antibiotics Among Patients Hospitalized for Exacerbations of Asthma.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Asthma; Black or African American; Cephalosporins; Comorbidity; Disease Progression; Female; Heart Failure; Hospitalization; Hospitals, Teaching; Humans; Inappropriate Prescribing; Macrolides; Male; Middle Aged; New England; Odds Ratio; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quinolones; Retrospective Studies; Southeastern United States; Tetracyclines; United States; White People | 2016 |
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Mice; Progeria; Quinolones | 2008 |
Olfactory disturbance in Parkinson disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain; Cognition Disorders; Constipation; Diagnosis, Differential; Disease Progression; Electroencephalography; Hallucinations; Humans; Levetiracetam; Lewy Body Disease; Male; Olfactory Pathways; Parkinson Disease; Piperazines; Piracetam; Quinolones; REM Sleep Behavior Disorder; Treatment Failure; Tremor | 2009 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Hospital Mortality; Humans; Macrolides; Male; Middle Aged; Multivariate Analysis; Patient Readmission; Pulmonary Disease, Chronic Obstructive; Quinolones; Retrospective Studies; Treatment Outcome | 2013 |
Use of enrofloxacin for treatment of large-form Haemobartonella felis in experimentally infected cats.
Topics: Anaplasmataceae; Anaplasmataceae Infections; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Case-Control Studies; Cat Diseases; Cats; Disease Progression; Dose-Response Relationship, Drug; Doxycycline; Enrofloxacin; Female; Fluoroquinolones; Hematocrit; Male; Polymerase Chain Reaction; Prospective Studies; Quinolones; Random Allocation; Specific Pathogen-Free Organisms; Treatment Outcome | 2002 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Aripiprazole and worsening of psychosis: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disease Progression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Recurrence | 2007 |
Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Biological Availability; Disease Progression; Endophthalmitis; Enterococcus faecalis; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Male; Ofloxacin; Ointments; Ophthalmic Solutions; Quinolones; Rabbits | 2008 |
[Use of maxaquin in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens].
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Disease Progression; Drug Resistance, Microbial; Fluoroquinolones; Follow-Up Studies; Humans; Middle Aged; Mycobacterium tuberculosis; Quinolones; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 1997 |
Onset and progression of motor deficits in motor neuron degeneration (mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)-deprenyl.
Topics: Animals; Disease Progression; Excitatory Amino Acid Antagonists; Female; Male; Mice; Mice, Mutant Strains; Monoamine Oxidase Inhibitors; Motor Activity; Motor Neuron Disease; Nerve Degeneration; Quinolones; Selegiline; Stereoisomerism | 1999 |